Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.47 |
| ▸ | JAK1 | P23458 | 6/20 | 0.47 |
| ▸ | JAK3 | P52333 | 6/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035314 | 0.92 | JAK2 (0.52) | JAK2JAK1JAK3GFEREGFR | |
| SCHEMBL15193797 | 0.90 | JAK2 (0.44) | JAK2JAK1JAK3GFEREGFR | |
| SCHEMBL2035051 | 0.89 | JAK3 (0.61) | JAK2JAK1JAK3FLT3 | |
| SCHEMBL2035052 | 0.89 | JAK3 (0.61) | JAK2JAK1JAK3FLT3 | |
| SCHEMBL2035068 | 0.88 | JAK2 (0.42) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL2033799 | 0.88 | FLT3 (0.44) | JAK2JAK1JAK3GFERIGF1R | |
| SCHEMBL2034765 | 0.87 | ADORA2A (0.41) | JAK2JAK1JAK3GFERADORA2A | |
| SCHEMBL2041813 | 0.87 | JAK2 (0.41) | JAK2JAK1JAK3GFEREGFR | |
| SCHEMBL2034442 | 0.86 | RAB9A (0.42) | JAK2JAK1JAK3GFEREGFR | |
| SCHEMBL2041787 | 0.86 | FPR2 (0.42) | JAK2JAK1JAK3GFERIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.